Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)

The recent revelation of the vast potential of P2Y₁₄R inhibitors has led to the development of novel compounds that exhibit promising capabilities for the treatment of sterile inflammation of the kidney, potentially diabetes, and asthma. Despite being a relatively nascent class of compounds, certain members have already exhibited their capacity to surmount specific challenges posed by conventional P2Y₁₄R inhibitors. Targeting P2Y₁₄R through small molecules may present a promising therapeutic strategy for effectively managing diverse inflammatory diseases.